Last updated on April 2019

Changes in Health and Functional Status in Patients With Chronic Obstructive Pulmonary Disease During Therapy With Spiolto Respimat (AERIAL )


Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Chronic Obstructive Lung Disease
  • Age: Between 40 - 100 Years
  • Gender: Male or Female

Inclusion Criteria:

Patients can be included if all of the following criteria are met:

  • Written informed consent prior to participation
  • Female and male patients 40 years of age
  • Patients diagnosed with COPD and requiring a combination of two long-acting bronchodilators (LAMA + LABA) according to approved SmPC and GOLD COPD guideline recommendation 2017 (GOLD COPD groups B to D)
  • Treatment with Spiolto Respimat acc. to SmPC at the discretion of the physician.

Exclusion Criteria:

  • Patients with contraindications according to Spiolto Respimat SmPC
  • Patients already on a LABA/LAMA combination (free and fixed dose) in the last 6 weeks before study entry
  • Patients continuing LABA-ICS treatment should not be additionally treated with Spiolto Respimat in order to avoid a double dosing of long-acting beta-agonists
  • Pregnancy and lactation
  • Current participation in any clinical trial or any other non-interventional study of a drug or device.

Recruitment Status: Closed


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.